Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26208101
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26208101
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 PLoS+One
2015 ; 10
(7
): e0133511
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Suramin Inhibits Chikungunya Virus Entry and Transmission
#MMPMID26208101
Ho YJ
; Wang YM
; Lu JW
; Wu TY
; Lin LI
; Kuo SC
; Lin CC
PLoS One
2015[]; 10
(7
): e0133511
PMID26208101
show ga
The mosquito-borne Chikungunya virus (CHIKV) is a profound global threat due to
its high rate of contagion and the lack of vaccine or effective treatment.
Suramin is a symmetric polyanionic naphthylurea that is widely used in the
clinical treatment of parasite infections. Numerous studies have reported the
broad antiviral activities of suramin; however, inhibition effects against CHIKV
have not yet been demonstrated. The aim of this study was thus to investigate the
antiviral effect of suramin on CHIKV infection and to elucidate the molecular
mechanism underlying inhibition using plaque reduction assay, RT-qPCR, western
blot analysis, and plaque assay. Microneutralization assay was used to determine
the EC50 of suramin in the CHIKV-S27 strain as well as in three other clinical
strains (0611aTw, 0810bTw and 0706aTw). Time-of-addition was used to reveal the
anti-CHIKV mechanism of suramin. We also evaluated anti-CHIKV activity with
regard to viral entry, virus release, and cell-to-cell transmission. Cytopathic
effect, viral RNA, viral protein, and the virus yield of CHIKV infection were
shown to diminish in the presence of suramin in a dose-dependent manner. Suramin
was also shown the inhibitory activities of the three clinical isolates. Suramin
inhibited the early progression of CHIKV infection, due perhaps to interference
with virus fusion and binding, which subsequently prevented viral entry. Results
of a molecular docking simulation indicate that suramin may embed within the
cavity of the E1/E2 heterodimer to interfere with their function. Suramin was
also shown to reduce viral release and cell-to-cell transmission of CHIKV. In
conclusion, Suramin shows considerable potential as a novel anti-CHIKV agent
targeting viral entry, extracellular transmission, and cell-to-cell transmission.
free
free
free
